Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.70 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.70 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 1/20 | 0.70 |
| ▸ | HTR2C | P28335 | 1/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.70 |
| ▸ | HRH1 | P35367 | 1/20 | 0.70 |
| ▸ | DRD3 | P35462 | 1/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5385866 | 0.92 | CHRM1 (0.64) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL7762277 | 0.89 | CHRM1 (0.48) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL5388888 | 0.88 | CHRM1 (0.59) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL28124938 | 0.88 | CA2 (0.61) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL5387018 | 0.87 | CHRM1 (0.57) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL5378303 | 0.87 | CHRM1 (0.57) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL140241 | 0.83 | CHRM1 (1.00) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL1330837 | 0.83 | CHRM1 (1.00) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Valproic Acid SCHEMBL2275 | 0.83 | CHRM1 (1.00) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL5389894 | 0.83 | CHRM1 (0.62) | CHRM1AKR1A1CHRM3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050267168-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2005-12-01 | — | — | US | claimed |
| US-20030096802-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-05-22 | — | — | US | claimed |
| US-6201021-B1 | TREATMENT OF DISEASES INDUCED BY REACTIVE ASTROCYTES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-03-13 | — | — | US | claimed |
| EP-0632008-B1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1998-02-04 | — | — | EP | claimed |
| EP-0632008-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-01-04 | — | — | EP | claimed |
| JP-6116200-A | — | — | None | — | — | JP | disclosed |
| US-8569058-B2 | Nerve regeneration promoters | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-7569608-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569608-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569609-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569609-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20070043114-A1 | Nerve regeneration promoters | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1089960-A1 | ALPHA-FLUORO ALKYNOIC ACIDS WITH ANTICONVULSANT ACTIVITY | AMERICAN BIOGENETIC SCIENCES, INC. (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6201021-B1 | TREATMENT OF DISEASES INDUCED BY REACTIVE ASTROCYTES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-03-13 | — | — | US | disclosed |
| US-6184401-B1 | ANTICONVULSANTS,-EPILEPTIC AGENTS; COMPARABLE TO VALPROIC ACID IN THEIR PREVENTION OF SEIZURES BUT HAVE REDUCED TERATOGENIC POTENTIAL, LONGER DURATION OF ACTION AND REDUCED SIDE EFFECTS | AMERICAN BIOGENETIC SCIENCES | 2001-02-06 | — | — | US | disclosed |
| WO-1999067195-A1 | ALPHA-FLUORO ALKYNOIC ACIDS WITH ANTICONVULSANT ACTIVITY | AMERICAN BIOGENETIC SCIENCES INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999067199-A1 | 2-FLUORO-2-ALKYL ALKANOAMIDES WITH ANTICONVULSANT ACTIVITY | AMERICAN BIOGENETIC SCIENCES INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| EP-0632008-B1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1998-02-04 | — | — | EP | disclosed |
| EP-0632008-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-01-04 | — | — | EP | disclosed |
| JP-H06116200-A | NEW FLUORINATED VALPROIC ACID DERIVATIVE AND ANTIEPILEPTIC AGENT | KUREHA CHEM IND CO LTD | 1994-04-26 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267168-A1 | Pentanoic acid derivatives | FFAR3, FFAR1, HCAR3 | CHRM1 93/4885AKR1A1 771/4885CHRM3 89/4885 |
| US-20070043114-A1 | Nerve regeneration promoters | BDNF, NGF, GAP43 | CHRM1 2671/4885AKR1A1 2042/4885CHRM3 2784/4885 |
| US-20030096802-A1 | Pentanoic acid derivatives | FFAR3, FPR1, FPR3 | CHRM1 84/4885AKR1A1 976/4885CHRM3 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.